Royalty Pharma
RPRX
RPRX
391 hedge funds and large institutions have $8.7B invested in Royalty Pharma in 2024 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 157 increasing their positions, 122 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
4% more funds holding
Funds holding: 375 → 391 (+16)
4% more capital invested
Capital invested by funds: $8.33B → $8.7B (+$370M)
1.28% less ownership
Funds ownership: 69.93% → 68.64% (-1.3%)
Holders
391
Holding in Top 10
9
Calls
$20.8M
Puts
$1.47M
Top Buyers
| 1 | +$56.3M | |
| 2 | +$44.5M | |
| 3 | +$38.5M | |
| 4 |
Charles Schwab
San Francisco,
California
|
+$31.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$27.4M |
Top Sellers
| 1 | -$182M | |
| 2 | -$132M | |
| 3 | -$86.4M | |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$30.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$28.8M |